BPM31510
AssetAlso called coenzyme q10, BPM31510 Nanosuspension Injection, BPM31510 Oral Nanosuspension 4%, Nanoquinone
Supports mitochondrial electron transport and antioxidant defenses.
- Stage
- Phase 3
- Modality
- Supplement
- Target
- Not known
- 21
- Indications
- 103
- Trials
- 7
- Developers
2 trials are still running. Development reported on Nov 9, 2026. bpgbio.com
Indications
21Parkinson's disease
Phase 3, Completed, NCT00180037, clinicaltrials.gov, Nov 13, 2026
Glioblastoma
Phase 2, Active not recruiting, NCT04752813, clinicaltrials.gov, Oct 17, 2026
Pancreatic cancer
Phase 2, Completed, NCT02650804, clinicaltrials.gov, Oct 17, 2026
18 more
In the full profile
- Target and mechanism1
- Owner and partners7
- Trials103
- Evidence for its targets1
- Competitors12
- Aging relevance2
- Signals7
Every asset’s record: target, stage, trials and the evidence behind it.